The use of a GnRH antagonist as the primary pituitary desensitizing agent during ovarian stimulation has enabled more appropriate treatment segmentation to drastically reduce the risk of OHSS (14–16). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.